IL-12A p35 Inhibitors

Chemical inhibitors of IL-12A p35 primarily function by modulating immune responses and signaling pathways that are crucial for the expression and function of IL-12A p35. These inhibitors do not directly target IL-12A p35; instead, they influence the cellular and molecular environment in which IL-12A p35 operates, thereby indirectly affecting its activity. The first group of inhibitors includes compounds like Dexamethasone, Budesonide, and Sulfasalazine, which inhibit the NF-κB pathway. NF-κB is a key transcription factor involved in the expression of many cytokines, including IL-12A p35. By inhibiting NF-κB activation, these compounds can reduce the expression of IL-12A p35, thus modulating the cytokine-mediated immune responses. For example, glucocorticoids like Dexamethasone and Budesonide suppress NF-κB activation, leading to reduced expression of IL-12A p35 and consequently impacting immune signaling pathways.

Another category of inhibitors includes Aspirin, Curcumin, and Hydroxychloroquine, which modulate various signaling pathways, including those related to inflammation and immune responses. Aspirin, by inhibiting cyclooxygenase enzymes, reduces prostaglandin production, which can lead to decreased activation of pathways that upregulate IL-12A p35. Curcumin, with its broad modulatory effects on signaling pathways including NF-κB, can also indirectly decrease IL-12A p35 expression. Hydroxychloroquine, commonly used in autoimmune diseases, can modulate immune responses, reducing IL-12A p35 expression. Rapamycin, Mycophenolate Mofetil, Methotrexate, and Azathioprine represent a group of inhibitors that act by altering cellular growth, metabolism, and immune responses. Rapamycin, through mTOR inhibition, modulates immune responses, which can lead to altered expression of IL-12A p35. Lastly, Thalidomide and Infliximab, by modulating immune responses and cytokine signaling, can also indirectly inhibit IL-12A p35. Infliximab, a TNF-α inhibitor, can indirectly affect the expression of IL-12A p35 by modulating the TNF-α pathway, which is involved in cytokine regulation. Thalidomide's impact on various aspects of immune signaling can lead to reduced IL-12A p35 expression.